Leonardo da Vinci is thought to have applied as many as thirty near-transparent layers of oil glaze to build the shadow at the corners of the Mona Lisa's mouth and eyes, each layer thin enough to let the one beneath show through, blended before any of them had time to set into a hard line. The technique carries a name that describes exactly what it does and does not do: sfumato, from the Italian sfumare, "to vanish like smoke." Its whole premise is the absence of an edge. A lesser portraitist draws a contour and fills it in; Leonardo dissolved the contour itself, so that shadow becomes skin becomes highlight without the eye ever finding the seam. Art historians still debate how many sessions the painting took, but the mechanism is not really in dispute: the effect is not the product of one layer. It is the product of enough thin, gradual layers that no single one is doing anything visible on its own.

I bring this up because it is close to the exact gap between expectation and mechanism that I hear from patients asking about injectable treatment for submental fat — what most people simply call a double chin, and what an increasing number now ask for by a more specific request: an injection instead of a scalpel, something that "dissolves" the fat rather than removing it. The mental model most people bring to that conversation is borrowed from liposuction — a defined volume of fat extracted in one session, with a result visible as soon as the swelling goes down. Deoxycholic acid injection lipolysis, studied under the name ATX-101, does not behave that way, and understanding why has more bearing on whether a patient is satisfied at week twelve than any number in the trial data.

What the Injection Actually Does to a Fat Cell

Deoxycholic acid is not a novel molecule invented for aesthetics. It is a bile acid the body already produces to help emulsify dietary fat in the small intestine — a detergent, chemically speaking. Injected into subcutaneous fat at a defined concentration, it behaves the same way there: it disrupts the membrane of the adipocyte, the fat cell, causing it to lyse and release its contents into the surrounding tissue (Rzany et al., 2014). Nothing about that step is instant or clean. What follows is a local inflammatory response in which macrophages — the immune system's cleanup cells — clear the released lipid and cellular debris over the following weeks, not the following hours. A liposuction cannula removes fat directly, in the room, under the surgeon's hand. A deoxycholic acid injection asks the patient's own immune system to do the removing, on a timeline the physician does not fully control.

What the Trial Data Actually Showed

The evidence base is unusually solid for an aesthetic injectable, built on twin phase III, randomized, placebo-controlled trials run in parallel as part of the same development program. In the arm reported by Rzany et al. (2014) in the British Journal of Dermatology (N = 363), 59.2% of patients treated at the lower dose and 65.3% at the higher dose were rated as clinical responders by blinded assessors, against 23.0% on placebo (p < .001); patient-reported satisfaction followed a similar pattern, at 53.3% and 66.1% versus 28.7%. The companion trial, published by Ascher et al. (2014) in the Journal of the European Academy of Dermatology and Venereology (N = 360), found comparable responder rates of 58.3% and 62.3% against 34.5% for placebo, again at p < .001. Neither trial is subtle about the drug working. What both are more careful about is timing: the primary endpoint in each was measured after multiple treatment sessions spaced roughly a month apart, not after a single visit — because a single session's worth of dissolved fat cells is, much like one of Leonardo's glazes, not something a mirror can register on its own.

Why the Edge Is Deliberately Blurred

This is also where technique starts to matter as much as the drug. Physicians are trained to mark the treatment area as a grid and to taper the injection density toward its border — fewer, smaller-volume injection points at the periphery than at the center — specifically so the boundary between treated and untreated fat does not resolve into a visible step. The goal is not a defined edge; it is a gradient the eye cannot locate, for the same reason Leonardo tapered his glazes rather than drawing a jawline in a single stroke. Get that gradient wrong, and the more common complaint isn't undertreatment — it's an unevenness at the margin of the treated area, a problem of blending, not of dose.

What the Larger Picture Adds — and Complicates

A 2023 systematic review and meta-analysis by Inocencio et al., pooling five randomized controlled trials and 1,837 patients in Clinics, confirmed the efficacy signal at scale — treated patients were between roughly 2.3 and 8.4 times more likely than placebo patients to meet various success thresholds, depending on which outcome measure was used. But the same review is unusually direct about the trade-off: pooled adverse event risk was substantially elevated relative to placebo across the board — fibrosis roughly 10 times more likely, numbness 13 to 22 times more likely, injection-site nodules nearly 6 times more likely, and pain 2 to 3 times more likely. A separate serious event, described in the Ascher et al. (2014) trial, was a temporary asymmetric smile from presumed injury to a branch of the marginal mandibular nerve, which runs directly through the treatment zone and resolved without intervention. The Inocencio review adds one more caveat that is worth stating plainly rather than glazing over: every one of the five trials it pooled was industry-funded, with several authors holding financial relationships to the manufacturer — a detail that does not invalidate the effect size, but that any patient deciding between an injection and a scalpel deserves to know sits underneath the numbers.

Leonardo did not paint a jawline and then blur it after the fact. He built the result out of layers thin enough that none of them, alone, looked like anything — and the finished face only exists because enough of those layers were laid down, correctly, over enough sessions. A deoxycholic acid injection works on roughly the same logic, biologically and technically: no single visit dissolves a double chin, no single injection draws a new jawline, and the treated area is designed, on purpose, to have no edge a patient can point to. The result, when it works, is not evidence of one dramatic session. It is evidence that enough gradual ones were done well.

References

Ascher, B., Hoffmann, K., Walker, P., Lippert, S., Wollina, U., & Havlickova, B. (2014). Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: Results from a phase III, randomized, placebo-controlled study. Journal of the European Academy of Dermatology and Venereology, 28(12), 1707–1715. https://doi.org/10.1111/jdv.12377

Inocencio, G. S. G., Meneses-Santos, D., Costa, M. D. M. de A., Vieira, W. A., Almeida, V. L. de, Rodrigues, R. P. C. B., Rode, S. de M., & Paranhos, L. R. (2023). Efficacy, safety, and potential industry bias in using deoxycholic acid for submental fat reduction—A systematic review and meta-analysis of randomized clinical trials. Clinics, 78, 100220. https://doi.org/10.1016/j.clinsp.2023.100220

Rzany, B., Griffiths, T., Walker, P., Lippert, S., McDiarmid, J., & Havlickova, B. (2014). Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: Results from a phase III, randomized, placebo-controlled study. The British Journal of Dermatology, 170(2), 445–453. https://doi.org/10.1111/bjd.12695